Introduction

Myasthenia Gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue. Antibodies target acetylcholine receptors at the neuromuscular junction, impairing signal transmission from nerves to muscles. The condition shows a bimodal age distribution, affecting women more commonly in their 20s-30s and men in their 60s-70s. Symptoms typically begin with ocular weakness (ptosis, diplopia) and may progress to involve bulbar, limb, and respiratory muscles. Diagnosis relies on antibody testing, electrophysiological studies, and clinical response to acetylcholinesterase inhibitors.

Myasthenia Gravis

Demographic Information

• Incidence: Approximately 1 in 10,000 to 1 in 20,000 people per year
• Prevalence: About 20 cases per 100,000 people
• Gender: More common in women under 40 and men over 60
• Onset Age: Bimodal distribution: women typically in their 20s-30s, men typically in their 60s-70s

Coding

• ICD-11: 8B44
• ICD-10-CM: G70.00
• OMIM: 254200
• UMLS: C0026896
• MeSH: D009157
• GARD: 7422

Quick Reference

| Quick Facts | Details | |-------------|---------| | Incidence | 4.1-30 per million person-years (U.S.: 68.5 per million; ~17,417 new cases annually) | | Prevalence | 150-329 per million (U.S.: 316.4 per million) | | Gender Distribution | Bimodal: more common in women under 40 and men over 60 | | Primary Age of Onset | Bimodal distribution: women typically 20s-30s, men typically 60s-70s | | AT/AAC Requirements | Low to Moderate - Many benefit from AT during exacerbations or myasthenic crisis; voice amplifiers for weak speech, SGDs for severe dysarthria; fluctuating needs based on disease activity |

Medical Features and Pathophysiology

Etiology

Myasthenia Gravis (MG) is an autoimmune disorder characterized by the production of antibodies that target the acetylcholine receptors (AChR) or other components of the neuromuscular junction (NMJ). This immune response interferes with the communication between nerve cells and muscles, leading to muscle weakness and fatigue. The exact cause of this autoimmune response is unknown, but genetic and environmental factors may contribute.

Pathology

MG primarily affects the NMJ, where nerve impulses are transmitted to muscles. In most cases, antibodies attack the AChR on muscle cells, reducing the number of available receptors and impairing muscle contraction. Some patients may have antibodies against other proteins, such as muscle-specific kinase (MuSK). The reduction in effective neuromuscular transmission leads to the characteristic symptoms of muscle weakness and fatigue, which can fluctuate in intensity.

Symptoms

• Early Symptoms:

- Diplopia (double vision) - Weakness in facial muscles - Difficulty swallowing (dysphagia) - Slurred speech (dysarthria)

• Progressive Symptoms:

- Difficulty breathing due to weakness of respiratory muscles - Weakness in arms and legs - Myasthenic crisis (severe muscle weakness causing respiratory failure)

Diagnosis

Diagnosis of MG involves clinical evaluation, including a detailed medical history and physical examination. Specific tests include:

• Antibody Tests: Detection of anti-AChR and anti-MuSK antibodies in the blood.
• Electrophysiological Studies: Repetitive nerve stimulation and single-fiber electromyography (SFEMG) to assess neuromuscular transmission.
• Edrophonium Test: Temporary improvement in muscle strength following administration of edrophonium, an acetylcholinesterase inhibitor.
• Imaging: CT or MRI to detect thymomas, which are associated with MG.

Assistive Suggestions and Requirements

Requirement Percentage for Assistive Technology

Many patients with MG will benefit from assistive technology, particularly during periods of exacerbation or myasthenic crisis.

Assistive Technology Suggestions

• Mobility Aids:

- Wheelchairs: For severe cases or during myasthenic crisis.

• Communication Aids:

- Speech Generating Devices (SGDs): For severe dysarthria.

• Home Modifications:

- Adjustable Beds: To improve comfort and ease of movement.

• Feeding Aids:

Access Modalities

• Switch Access: For individuals with severe motor impairments to control communication devices and computers.
• Voice-Controlled Systems: Beneficial for those who retain good vocal strength.
• Touchscreen Devices: Useful for those with adequate hand dexterity.

Care Management and Therapeutic Techniques

Aims

• To manage symptoms and maintain the highest possible level of independence and quality of life.
• To provide supportive care and address complications through a multidisciplinary approach.
• To offer education and support to patients and caregivers.

SLP Suggestions

• Assessment and Intervention:

- Swallowing Techniques: Teaching techniques to ensure safe swallowing and reduce the risk of aspiration. - Voice Therapy: Exercises to maintain voice strength and clarity.

• Augmentative and Alternative Communication (AAC):

Special Educator Suggestions

• Cognitive Rehabilitation:

- Use of memory aids, such as notebooks or electronic organizers.

• Behavioral Strategies:

- Positive reinforcement to encourage participation and effort in tasks.

Occupational Therapist Suggestions

• Daily Living Skills:

- Techniques to conserve energy and manage fatigue.

• Home and Environmental Modifications:

- Recommendations for ergonomic furniture and tools to support independence.

Recommendations on AAC and Other Details

• Text-Based AAC:

- Predictive text features to speed up communication.

• Symbol-Based AAC:

- Dynamic display devices that can grow with the user’s needs.

Clinical Information

Core Characteristics

• Etiology: Autoimmune
• Pathology: Ideopathic
• Rarity Classification: Medium
• Typical Onset: Any Age
• Gender Impact: Either Gender
• Seizure Prevalence: No (<10%)
• Population Trend: Increasing

Pathophysiology

"Grave weakness;" error in nerve impulse transmission to muscles (PNS). Origins typically unknown, and even duration of impact can be variable.

AAC Considerations

Additional Clinical Notes

Autoimmune disorder causing chronic fatigue with variable severity

Patient Advocacy & Support Organizations

• https://myasthenia.org/

References

1. alchalabi. (2012). 2. alasmi. (2012). 3. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Myasthenia-Gravis-Fact-Sheet

Additional Information

MG requires ongoing neurological management with regular assessment of treatment efficacy and disease activity. Monitoring for myasthenic crisis and respiratory complications is essential, particularly during infections or medication changes. Coordination between neurology, pulmonology, and rehabilitation services optimizes functional outcomes and quality of life.

Extended Information

Pathological Insights and Disease Mechanism

Myasthenia Gravis (MG) is characterized by the production of autoantibodies that disrupt neuromuscular transmission, leading to muscle weakness and fatigue. In most patients, these antibodies target the acetylcholine receptor (AChR) at the neuromuscular junction. A smaller subset of patients has antibodies against muscle-specific kinase (MuSK) or other components of the neuromuscular junction. The presence of these autoantibodies reduces the number of functional AChRs, impairs synaptic transmission, and ultimately weakens muscle contractions. The exact triggers for the autoimmune response are not fully understood, but genetic predisposition, infections, and other environmental factors are thought to play a role.

Genetic and Environmental Factors

While MG is primarily an autoimmune disorder, genetic factors may contribute to the susceptibility to developing the disease. Certain genetic polymorphisms in immune-related genes have been associated with an increased risk of MG. Environmental factors, such as viral infections, have also been implicated in triggering the autoimmune response. The interplay between genetic predisposition and environmental triggers is an area of active research, aiming to uncover the underlying mechanisms that lead to the development of MG.

Clinical Presentation and Disease Progression

The clinical presentation of MG varies widely among individuals. The hallmark symptoms include fluctuating muscle weakness and fatigue, which worsen with activity and improve with rest. The disease often begins with ocular symptoms, such as ptosis (drooping eyelids) and diplopia (double vision), which may progress to generalized muscle weakness. In some cases, MG can lead to severe respiratory muscle weakness, resulting in myasthenic crisis—a life-threatening condition that requires immediate medical attention. The course of the disease can be variable, with some patients experiencing periods of remission and others having a progressive decline in muscle strength.

Differential Diagnosis and Overlapping Syndromes

Diagnosing MG involves differentiating it from other neuromuscular disorders that can present with similar symptoms. Conditions such as Lambert-Eaton Myasthenic Syndrome (LEMS), botulism, and primary muscle diseases need to be considered. A thorough clinical evaluation, including a detailed history, physical examination, and appropriate diagnostic tests, is essential for an accurate diagnosis. Electrophysiological studies and antibody testing are particularly important for confirming MG and ruling out other conditions.

Therapeutic Interventions and Symptom Management

The management of MG involves a combination of pharmacological and non-pharmacological treatments aimed at improving neuromuscular transmission, suppressing the autoimmune response, and managing symptoms. Acetylcholinesterase inhibitors, such as pyridostigmine, are commonly used to enhance neuromuscular transmission and alleviate muscle weakness. Immunosuppressive therapies, including corticosteroids, azathioprine, and mycophenolate mofetil, are used to reduce

the production of autoantibodies and modulate the immune response. Intravenous immunoglobulin (IVIG) and plasmapheresis rapidly reduce antibody levels during myasthenic crises or before surgery. Thymectomy is recommended for individuals with thymoma or generalized MG, potentially leading to long-term remission.

Research and Future Directions

Research focuses on understanding autoimmune mechanisms and developing targeted immunotherapies. Monoclonal antibodies targeting specific immune system components show promise in clinical trials. Biomarker development aims to improve early diagnosis and disease monitoring.

Support and Resources

Organizations such as the Myasthenia Gravis Foundation of America (MGFA) and Myaware provide educational materials, support networks, and research advocacy. Support groups offer platforms for sharing experiences and accessing practical guidance.

Epidemiology and Demographics

Etiology and Pathophysiology

Clinical Features and Stages

Diagnosis

Clinical Recommendations

Care Management

Transition Planning